Introduction of foreign cell therapy product regulatory system and enlightenment to China.

National Policy for the Cellular Gene Industry (as of September 2023)

Clinical history of gene therapy

Shanghai's biomedical industry has a total scale of nearly 900 billion yuan, and has formed advantageous industrial clusters in the fields of cell and gene therapy, synthetic biology, AI+ pharmaceutical, and medical robots.

The second human case of gene-edited pig heart transplantation is completed: Thoughts on xenogenic organ transplantation after gene-edited modification!

China's first national standard for personally-derived stem cells has been released in Chongqing.

The treatment survival rate is over 87%, and the stem cell type bioartificial liver project has been approved for clinical use and is being promoted for commercialization.

With financial support of up to 30 million yuan, Shanghai issued the Shanghai Action Plan for promoting Gene Therapy Scientific and technological Innovation and Industrial Development (2023-2025).